1. Bone R.C., Balk R.A., Cerra F.B. et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest 2009; 136 (Suppl 5): e28.
2. Сепсис в начале XXI века. Практическое руководство. Под ред. В.С. Савельева, Б.Р. Гельфанда. М: Литтерра 2006.
3. Сепсис: классификация, клинико-диагностическая концепция и лечение. Практическое руководство. Под ред. В.С. Савельева, Б.Р. Гельфанда. 2-е изд. М: МИА 2011.
4. Мороз В.В., Лукач В.Н., Шифман Е.М. и др. Сепсис: клинико-патофизиологические аспекты интенсивной терапии: руководство для врачей. Петрозаводск: ИнтелТек 2004.
5. Dellinger R.P., Levy M.M., Rhodes A. et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39 (2): 165-228.
6. Fein A.M., Fink M.P., Bone R.C. et al. Sepsis and Multiorgan Failure. Philadelphia: Saunders 2002.
7. Бокерия Л.А., Белобородова Н.В. Инфекция в кардиохирургии. М: НЦССХ им. А.Н. Бакулева РАМН 2007.
8. Bernard G.R., Vincent J.L., Laterre P.F. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344 (10): 699-709.
9. Vincent J.L., Abraham E. The last 100 Years of Sepsis. Am J Respir Crit Care Med 2006; 173 (3): 256-263.
10. Abraham E., Reinhart K., Opal S. et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290 (2): 238-247.
11. Warren B.L., Eid A., Singer P. et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286 (15): 1869-1878.
12. Ranieri V.M., Thompson B.T., Barie P.S. et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366 (22): 2055-2064.
13. Iba T., Aihara K., Watanabe S. et al. Recombinant thrombomodulin improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat LPS model. Thromb Res 2013; 131 (4): 295-299.
14. Saito H., Maruyama I., Shimazaki S. et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5 (1): 31-41.
15. A Randomized, Double-Blind, Placebo-Controlled, Phase-2B Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients with Sepsis and Suspected Disseminated Intravascular Coagulation. [Электронный ресурс]: http://www.artisanpharma.net/news.htm
16. Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy. [Электронный ресурс]: http://clinicaltrials.gov/ct2/show/NCT01598831?term=ART-123&rank=2
17. Iba T., Nagaoka I., Boulat M. The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation. Thromb Res 2013; 131 (5): 383-389.
18. Carlet J.M., Artigas A., Niederman M.S., Torres A. The Barcelona Declaration from the World Alliance against Antibiotic Resistance: engagement of intensivists. Crit Care 2012; 16 (4): 145.
19. Crowder F.M., Conly J.M., Surette M.G. A microbiome approach to sepsis: development and case-study application of novel methods for detection and isolation of microbes from whole blood. Critical Care 2012; 16 (Suppl 3): P111.
20. Puca E., Pipero P., Pilaca A. et al. Evaluation of procalcitonin in patients with sepsis in Albanian adults. Critical Care 2012; 16 (Suppl 3): P116.
21. McAllister K., Sheridan-Pereira M., O'Sullivan N. et al. Clinical utility of using C-reactive protein and procalcitonin as biomarkers for a novel neonatal sepsis diagnostic platform (ASCMicroPlat). Critical Care 2012; 16 (Suppl 3): P106.
22. Tang B.M.P., Eslick G.D., Craig J.C., McLean A.S. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007; 7 (3): 210-217.
23. Bouadma L., Luyt Ch.-E., Tubach F. at al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375 (9713): 463-474.
24. Afshari A., Harbarth S. Procalcitonin as diagnostic biomarker of sepsis. Lancet Infect Dis 2013; 13 (5): 382-384.
25. Cand C.W., Cand A.P., Brunkhorst F.M., Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 2013; 13 (5): 426-435.
26. Jensen J.U., Hein L., Lundgren B. et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit. Crit Care Med 2011; 39: 2048-2058.
27. Riedel S. Procalcitonin and antibiotic therapy: Can we improve antimicrobial stewardship in the intensive care setting? Care Med 2012; 40 (8): 2499-2450.
28. Lassalle P., Freitas Caires N.De., Portier L. et al. Endothelial cell specific molecule 1 is today a relevant marker of respiratory failure in sepsis and polytrauma patients. Critical Care 2012; 16 (Suppl 3): P110.
29. Göschl J., Sudhoff L., Koehler M. et al. Is urinary kidney injury molecule-1 a good marker for acute kidney injury in septic shock? Critical Care 2012; 16 (Suppl 3): P59.
30. Gukasjan R., Raptis D., Schulz H.U. et al. Pancreatic stone protein: a new predictor of outcome in patients with peritonitis. Critical Care 2012; 16 (Suppl 3): P62.
31. Патент US 2011/0086381 A1, Katsuki Naito (Mochida Pharmaceutical Co., Ltd.)
32. Naito K., Shirakawa K., Naitou K. et al. The new sepsis marker, sCD14-ST, Induction mechanism in the rabbit sepsis models. Critical Care 2010; 14 (Suppl 2): P19.
33. Kuchler L., Morbitzer V., Heeg A. et al. Attenuated NOX2 expression impairs ROS production during the hypoinflammatory phase of sepsis. Critical Care 2012; 16 (Suppl 3): P51.
34. Crawford B., Skeath M., Kaiser W.A. Permanente Northern California sepsis mortality reduction initiative. Critical Care 2012; 16 (Suppl 3): P12.
35. Daneman N., Sarwar S., Fowler R.A., Cuthbertson B.H. Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis. Lancet Infect Dis 2013; 13 (4): 328-341.
36. Vincent J.L., Nelson D.R., Williams M.D. Is worsening multiple organ failure the cause of death in patients with severe sepsis? Crit Care Med 2011; 39 (5): 1050-1055.
37. Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348 (2): 138-150.
38. Singer M. Mitochondrial function in sepsis: acute phase versus multiple organ failure. Crit Care Med 2007; 35 (Suppl 9): S441-448.
39. Singer M. Cellular Dysfunction in Sepsis. Clin Chest Med 2008; 29 (4): 655-660.
40. Frost M.T., Wang Q., Moncada S., Singer M. Hypoxia accelerates nitric oxide-dependent inhibition of mitochondrial complex I in activated macrophages. Am J Physiol Regul Integr Comp Physiol 2005; 288 (2): R394-400.
41. Gill S.R., Pop M., Deboy R.T. et al. Metagenomic analysis of the human distal gut microbiome. Science 2006; 312: 1355-1359.
42. Shenderov B.A. Modern condition and prospective host microecology investigations. Microb Ecol Health Dis 2007; 19: 145-149.
43. Shenderov B.A. Metabiotics: novel idea or naturaldevelopment of probiotic conception. Microb Ecol Health Dis 2013; 24: 20399. [Электронный ресурс]: http://dx.doi.org/10.3402/mehd.v24i0.20399
44. Патент на изобретение "Способ лабораторной диагностики сепсиса" № 2423704 от 10.07.2011. Белобородова Н.В., Оленин А.Ю., Ходакова А.С.
45. Fedotcheva N.I., Kazakov R.E., Kondrashova M.N., Beloborodova N.V. Toxic Effects of Microbial Phenolic Acids on the Functions of Mitochondria. Toxycology Letters 2008; 180: 182-188.
46. Федотчева Н.И., Теплова В.В., Белобородова Н.В. Участие фенольных кислот микробного происхождения в дисфункции митохондрий при сепсисе. Биол мембраны 2010; 1: 60-66.
47. Федотчева Н.И., Теплова В.В., Белобородова Н.В. Роль тиоловых антиоксидантов в восстановлении функций митохондрий, модифицированных микробными метаболитами. Биофизика 2012; 5: 820-826.
48. Белобородова Н.В., Байрамов И.Т., Оленин А.Ю., Федотчева Н.И. Экзометаболиты некоторых анаэробных микроорганизмов микрофлоры человека. Биомед хим 2011; 1: 95-105.
49. Белобородова Н.В., Байрамов И.Т., Оленин А.Ю. и др. Роль микробных экзометаболитов в гипоксической дисфункции митохондрий при сепсисе. Патогенез 2011; 3: 19.
50. Белобородова Н.В. Интеграция метаболизма человека и его микробиома при критических состояниях. Общая реаниматол 2012; 4: 42-54.
51. Белобородова Н.В., Оленин А.Ю., Ходакова А.С. и др. Происхождение и клиническое значение низкомолекулярных фенольных метаболитов в сыворотке крови человека. Анестезиол и реаниматол 2012; 5: 37-41.
52. Beloborodova N., Bairamov I., Olenin A. et al. Effect of phenolic acids of microbial origin on production of reactive oxygen species in mitochondria and neutrophils. J Biomed Sci 2012; 19: 89.
53. Beloborodova N.V., Olenin A.Y., Fedotcheva N.I. et al. Effect of phenolic acids originating from microbes on mitochondria and neutrophils. Critical Care 2012; 16 (Suppl 3): P26.

________________________________________________

N.V. BELOBORODOVA

N.I. Pirogov Russian National Research Medical University, Moscow